Correlation between Serum Total Testosterone and the AMS and IIEF Questionnaires in Patients with Erectile Dysfunction with Testosterone Deficiency Syndrome by Kang, Jae Il et al.
Korean Journal of Urology
Ⓒ The Korean Urological Association, 2011 416 Korean J Urol 2011;52:416-420
www.kjurology.org
DOI:10.4111/kju.2011.52.6.416
Sexual Dysfunction
Correlation between Serum Total Testosterone and the AMS and 
IIEF Questionnaires in Patients with Erectile Dysfunction with 
Testosterone Deficiency Syndrome
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Purpose: This study was conducted to investigate the relationship between serum total 
testosterone levels and scores on the Aging Male’s Symptom (AMS) scale and the 
International Index of Erectile Function (IIEF) in men with erectile dysfunction with 
testosterone deficiency syndrome (TDS).
Materials and Methods: From January 2005 to July 2008, 134 patients who complained 
of sexual dysfunction such as erectile dysfunction or decreased libido as the main symp-
toms of TDS with serum total testosterone levels less than 3.5 ng/ml were evaluated 
by independent t-test and linear regression analysis, respectively. Patients with treat-
ed hypogonadism within 6 months, with a history of taking a PDE5 inhibitor or an anti-
depressant for a depressive disorder, or who had metabolic syndrome were excluded 
from this study.
Results: The AMS scale and its 3 subdomain scores were not significantly correlated 
with the total testosterone level. By contrast, the total IIEF score and the score of each 
IIEF domain except sexual desire showed a weakly significantly positive correlation 
with serum total testosterone.
Conclusions: In TDS patients with erectile dysfunction, there was a low relationship 
between serum total testosterone levels and the AMS scale and a weakly positive corre-
lation between total testosterone levels and all IIEF domains except sexual desire. 
There was a low relationship between the AMS scale, the sexual desire domain score 
of the IIEF, and total testosterone. We should understand these limitations when evalu-
ating patients with erectile dysfunction with TDS. New scales should be developed for 
the evaluation of erectile dysfunction in these patients.
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INTRODUCTION
Late-onset hypogonadism or age-associated testosterone 
deficiency syndrome (TDS) in the aging male is defined as 
a clinical and biochemical syndrome characterized by a de-
cline in levels of serum testosterone. With aging, men expe-
rience decreases in important health indicators like muscle 
amount, muscle power, physical activity, bone density, 
blood generation, and sexual drive [1]. Various research 
[2-4] on the decrease in blood testosterone with aging sug-
gests that many clinical characteristics related to age, in-
cluding erectile dysfunction (ED), are closely related to lack 
of testosterones. Recent research results indicate that tes-
tosterone and ED are closely related to one other [5,6], 
which suggests that supplementary therapy with testos-
terone may be one useful method in the treatment of ED. 
For such a reason, the European Association of Urology 
Guideline (EAU Guideline) recommends that patients who 
come to clinics with ED as their main complaint should all 
undergo testosterone value testing [7].Korean J Urol 2011;52:416-420
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TABLE 1. Characteristics of the patients
Variables Mean±SD
Age (yr) 56.1±9.39
Testosterone (ng/ml) 2.71±0.76
AMS scale
　Psychological factor 8.76±4.13
　Somatovegetative factor 14.7±5.80
　Sexual factor 14.2±4.48
　Total score 37.6±12.5
IIEF questionnaire
　Erectile function 11.9±7.54
　Intercourse satisfaction 4.76±3.42
　Orgasmic function 4.61±3.40
　Sexual desire 4.52±1.94
　Overall satistaction 4.14±1.90
　Total score 29.9±16.1
SD: standard deviation, AMS: Aging Male’s Symptoms, IIEF: 
International Index of Erectile Function
FIG. 1. Correlation of serum total testosterone and IIEF scores. 
TT: total testosterone, IIEF: International Index of Erectile 
Function.
　Although there is no established standard for the diag-
nosis of TDS, the 2006 recommendation by the Korean 
Society of Aging Male Research is a serum total testoster-
one level of less than 12 nmol/l (3.46 ng/ml) or a free testos-
terone value of less than 250 pmol/l (72 pg/ml) [8]. Further-
more, changes in male hormones with aging vary among 
individuals [9], and the relationship between the degree of 
age-related symptoms and the reduction of male hormones 
is not clear. Therefore, for easy clinical diagnosis of TDS, 
not only the concentration of blood testosterone but also 
subjective symptoms surveyed by questionnaire are very 
important.
　The Aging Male’s Symptom (AMS) scale is the most wide-
ly used questionnaire for the diagnosis of TDS, but the AMS 
has been known to be nonspecific to low testosterone [10] 
because it was developed on the basis of a normal aging 
population.
　The International Index of Erectile Function (IIEF) is 
the most widely used questionnaire for the diagnosis and 
for assessing the treatment outcome of sexual dysfunction, 
but the IIEF has not been related to serum testosterone lev-
el because it was developed to evaluate the efficacy of phos-
phodiesterase-5 inhibitors (PDE5 inhibitors) in patients 
with ED [11,12].
　Despite these limitations, the AMS and IIEF are com-
monly used to assess the efficacy of testosterone replace-
ment therapy in ED patients with TDS. We performed this 
study to investigate the relationship between serum total 
testosterone levels and scores on the AMS scale and the 
IIEF and the threshold total testosterone level in relation 
to domains of the IIEF.
MATERIALS AND METHODS
This study was done on 134 outpatients in our clinics of ur-
ology with the main complaint of sexual dysfunction such 
as ED or decreased libido as the main symptom of TDS. The 
patients had a serum testosterone level less than 3.5 ng/ml 
and were evaluated from January 2005 to July 2008. 
Patients who received testosterone replacement therapy 
within 6 months, those taking type 5 phosphodiesterase 
(PDE5) inhibitors, those who were diagnosed with elderly 
depression and were taking anti-depressants, and those 
who had metabolic syndrome were excluded through gath-
ering of disease history.
　Patients underwent measurement of blood total testos-
terones through a blood test. Blood was collected between 
07:00 and 10:00 during an outpatient visit, at which time 
the patients also completed the AMS and IIEF question-
naires. The AMS scale was classified into three domains 
(psychological, somato-vegetative, and sexual) and the 
IIEF questionnaire sheet into five domains (erectile func-
tion, intercourse satisfaction, orgasmic function, sexual 
desire, and overall satisfaction). Serum total testosterone 
value, AMS total points and points for the three domains, 
and IIEF total points and points for the five domains were 
respectively analyzed.
　To determine the correlations of serum testosterone lev-
els with scores on the IIEF and AMS scale, linear regression 
analysis was used and correlation coefficients and p-values 
were determined. To determine the threshold testosterone 
level, independent t-tests were also used with SPSS ver. 
13.0 (SPSS Inc., Chicago, IL, USA). p-values of less than 
0.05 were considered to be statistically significant.
RESULTS
The average age of the patients was 56.1±9.39 years, and 
the average value of serum total testosterones was 2.71± 
0.76 ng/ml. In the AMS, the average value of the psycho-
logical symptom, somato-vegetative symptom, and sexual 
symptom domains were, respectively, 8.76±4.13, 14.7±5.80, 
and 14.2±4.48, and the average total points was 37.6±12.5. 
In the IIEF, the average values of each domain were, re-
spectively, 11.9±7.54 for erectile function, 4.76±3.42 for Korean J Urol 2011;52:416-420
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TABLE 2. Correlations of testosterone and multi-vocal factors in
TDS patients
Correlation coefficient  p-value
AMS scale
　Psychological factor 0.131 0.168
　Somatovegetative factor 0.101 0.289
　Sexual factor 0.015 0.875
　Total score 0.095 0.318
IIEF questionnaire
　Erectile function 0.141 0.021
　Intercourse satisfaction 0.126 0.049
　Orgasmic function 0.173 0.018
　Sexual desire 0.127 0.561
　Overall satisfaction 0.099 0.040
　Total score 0.124 0.034
TDS: testosterone deficiency syndrome, AMS: Aging Male’s
Symptoms, IIEF: International Index of Erectile Function
sexual satisfaction, 4.61±3.40 for orgasmic function, 4.52± 
1.94 for sexual drive, and 4.14±1.90 for overall satisfaction 
with sexual life, and the average total points was 29.9±16.1 
(Table 1).
　In the correlation analysis, serum total testosterone was 
not significantly correlated with the AMS total score or its 
3 subdomains (p＞0.05). Serum total testosterone showed 
a significant weakly positive correlation (r=0.124, p=0.034) 
with the IIEF total score (Fig. 1), and among the 5 domains, 
the domains of erectile function, intercourse satisfaction, 
orgasmic satisfaction, and overall satisfaction with sexual 
life also showed significant weakly positive correlations 
with serum total testosterone (p＜0.05). However, the sex-
ual drive domain did not show any correlation with serum 
total testosterone (Table 2).
DISCUSSION
Reduction in blood total testosterones with aging was de-
scribed for the first time by Hollander et al in the late 1950s 
and was verified in various cross-sectional studies and lon-
gitudinal studies [13-18]. Reduction of androgen accom-
panied by aging can cause physiological, somato-vegeta-
tive, and sexual symptoms, and the sexual symptoms in-
clude hyposexuality, ED, reduction of orgasmic function, 
and reduction of ejaculation amount and ejaculation force 
[19-21]. Testosterone deficiency causes sexual dysfunction 
and anatomical, physiological, and biochemical substrate 
damage of erectile function and affects the erection mecha-
nism in the penis organ but can be recovered through tes-
tosterone supplementation therapy. Some study results 
have indicated that aged males require higher concen-
trations of testosterones for normal sexual function than 
do young people. These findings support the importance of 
male hormones as represented by testosterone regarding 
the sexual dysfunction that occurs with aging [22].
　Sexual hormones are widely studied under the assump-
tion that sexual dysfunction symptoms are related to the 
conditions of sexual hormones, but some patients with sex-
ual dysfunction remain within the normal range of blood 
testosterone values [19-21]. Therefore, the correlation be-
tween high age itself and symptoms caused by aging leaves 
potential for argument, because aging-related symptoms 
can be affected by various causes such as hereditary fac-
tors, living habits, physical activity, nutritional status, and 
chemical dosage and accompanying diseases as well as en-
docrine changes. For such reasons, whether a patient’s 
symptoms are alleviated as well as blood testosterone con-
centration is marked in a self-administered symptom score 
table, but in practice there is no internationally recognized 
method of diagnosis that can be used for the determination 
of diagnosis and treatment progress.
　The most frequent reason that patients with reduced 
male hormone visit a urologist is sexual dysfunction, such 
as hyposexuality or reduction of sexual drive, and in this 
regard, the IIEF of Rosen et al and the sexual area of the 
AMS of Heinemann can be used [10,11]. In the present 
study, the AMS total score and the 3 subdomains showed 
a positive but not a significant correlation (p＞0.05) with 
total testosterone.
　In 2005 Morley et al specified male hormone deficiency 
condition as 70 ng/ml or less of bioavailable testosterones 
and compared the questionnaires of the Androgen Defi-
ciency in Aging Males (ADAM), the AMS, and the Massa-
chusetts Male Aging Study (MMAS). The diagnostic sensi-
tivities of each questionnaire were, respectively, 98%, 83%, 
and 60%, and the specificities were, respectively, 30%, 39%, 
and 59% [23]. It was reported that the patients who showed 
a positive reaction in each questionnaire showed a sig-
nificant difference in free testosterone and bioavailable 
testosterones but did not show any difference in total 
testosterones. In addition, in 2005 Basar et al determined 
more than 29 points in the total score of the AMS to be a 
positive reaction accompanied with aging and defined less 
than 26 points in the IIEF as hyposexuality in 348 persons 
[24]. In the AMS survey, patients with a positive reaction 
had significant differences in age, DHEA-A, estradiol, and 
AMS total points and points for each range compared with 
patients who did not have a positive reaction. Patients with 
hyposexuality had significant differences in age, DHEA-S, 
FTI, IIEF points, and AMS points. However, total testos-
terone was not associated with any variable. As mentioned 
above, the AMS survey is often used to screen patients with 
a lack of male hormone by total testosterone, but has low 
singularity and is not associated with total testosterone. 
These results may be because in the AMS survey, the items 
are questions associated with aging and do not reflect defi-
cient status of testosterone, and the male hormone value 
is not considered in the judgment of results. In the future, 
it is necessary to reevaluate the questions of the AMS survey 
and to correct and supplement them translated in Korean 
as a tool for the diagnosis and evaluation of age-associated 
TDS. 
　The IIEF was designed to measure erection ability and 
to evaluate a medical effect of impotence. In 2006, Zitzmann Korean J Urol 2011;52:416-420
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et al analyzed the relationship between male menopause 
and blood testosterone values in 434 males aged 50-86 
years old who suffered from the male menopause syndrome 
and reported that, according to reduced blood total testos-
terone value, syndromes such as sexual disinclination, obe-
sity, lack of concentration, somnipathy, and impotence 
were significantly increased [25]. The study also disclosed 
that there were significant positive correlations between 
blood total testosterone and IIEF total points and the 
points in the four ranges of erection ability, sex satisfaction, 
orgasm, and general satisfaction for sex life. However, with 
regard to sexual desire, the testosterone value was not cor-
related and many patients had normal sexual desire. 
Actually, it is reported that the numerical testosterone val-
ue required to maintain sexual desire is somewhat low. 
Some have reported that the numerical value of testoster-
one was not largely associated with sexual desire, although 
others strived to disclose a correlation between the numer-
ical value of testosterone and sexual desire [26]. Therefore, 
to evaluate sexual desire, the relationship of blood total tes-
tosterone with psychological factors such as stress and mel-
ancholy and chronic disease such as lack of sleep should be 
considered. 
　This study analyzed correlations between blood total tes-
tosterone value and scores related to sexual function syn-
dromes in hospital visitors with hyposexuality such as im-
potence and sexual disinclination. Our study differs from 
the existing domestic research carried out with male per-
sons of more than a fixed age. It is a limit of the study that 
this was a quantitative analysis of the numerical value of 
male hormone with only the AMS and IIEF as tools for 
measuring syndromes. Our study does not reflect the di-
verse endocrine changes that had an effect on the syn-
dromes because we measured only blood total testosterone 
as a method of biochemical diagnosis. Male hormone re-
placement therapy is now the main therapy of age-asso-
ciated TDS. Therefore, it is thought that it is necessary to 
carry out a large-scale research study on the correlations 
between male hormone values and survey results before 
and after carrying out male hormone replacement therapy. 
There are many reports that other hormones such as free 
testosterone, bioavailable testosterone, E2, and DHEA-S 
are associated with clinical syndromes such as impotence. 
Therefore, it is necessary to carry out research including 
the above in the future. 
CONCLUSIONS
In TDS patients with ED, there was a low relationship be-
tween serum total testosterone levels and the AMS scale 
and a weekly positive correlation between the total testos-
terone level and IIEF scores, except for sexual desire. 
Because there was a low relationship between the AMS, the 
sexual desire domain score of the IIEF, and total testoster-
one, we should understand these limitations of evaluating 
TDS patients with ED and develop a new scale to be used 
in the evaluation of these patients.
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